The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT

AIDS Research and Therapy

Volumn 5, Issue , 2008, Pages

  Kutscher, Sarah ^a   Dembek, Claudia J ^a   Allgayer, Simone ^a,b   Heltai, Silvia ^c   Stadlbauer, Birgit ^a,d   Biswas, Priscilla ^c   Nozza, Silvia ^c   Tambussi, Giuseppe ^c   Bogner, Johannes R ^e   Stellbrink, Hans J ^f   Goebel, Frank D ^e   Lusso, Paolo ^c   Tinelli, Marco ^g   Poli, Guido ^c,h   Erfle, Volker ^a   Pohla, Heike ^a,d   Malnati, Mauro ^c   Cosma, Antonio ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MUNICH   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f IPM Study Center   (Germany)

^g Hospital of Lodi   (Italy)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ANALYTIC METHOD; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELLULAR IMMUNITY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; INTRACELLULAR CYTOKINE STAINING; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS;

EID: 54349092626     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-5-22     Document Type: Article

References (34)

1. Hanke T McMichael AJ Dorrell L Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction J Gen Virol 2007, 88:1-12 10.1099/vir.0.82493-0 17170430
2. Gudmundsdotter L Sjodin A Bostrom AC Hejdeman B Theve-Palm R Alaeus A Lidman K Wahren B Therapeutic immunization for HIV Springer Semin Immunopathol 2006, 28:221-30 10.1007/s00281-006-0029-0 17031650
3. Yang OO Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes Aids 2008, 22:325-31 18195558
4. Russell ND Hudgens MG Ha R Havenar-Daughton C McElrath MJ Moving to human immunodeficiency virus type 1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity J Infect Dis 2003, 187:226-42 10.1086/367702 12552447
5. Janetzki S Schaed S Blachere NE Ben-Porat L Houghton AN Panageas KS Evaluation of Elispot assays: Influence of method and operator on variability of results J Immunol Methods 2004, 291:175-83 10.1016/ j.jim.2004.06.008 15345315
6. Samri A Durier C Urrutia A Sanchez I Gahery-Segard H Imbart S Sinet M Tartour E Aboulker JP Autran B Venet A Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay Clin Vaccine Immunol 2006, 13:684-97 1489560 16760328 10.1128/CVI.00387-05
7. Gudmundsdotter L Bernasconi D Hejdeman B Sandstrom E Alaeus A Lidman K Ensoli B Wahren B Butto S Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles Vaccine 2008, 26(40):5182-5187 10.1016/ j.vaccine.2008.03.094 18479789
8. Tassignon J Burny W Dahmani S Zhou L Stordeur P Byl B De Groote D Monitoring of cellular responses after vaccination against tetanus toxoid: Comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR J Immunol Methods 2005, 305:188-98 10.1016/j.jim.2005.07.014 16157348
9. Tobery TW Dubey SA Anderson K Freed DC Cox KS Lin J Prokop MT Sykes KJ Mogg R Mehrotra DV Fu TM Casimiro DR Shiver JW A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects AIDS Res Hum Retroviruses 2006, 22:1081-90 10.1089/aid.2006.22.1081 17147493
10. Karlsson AC Martin JN Younger SR Bredt BM Epling L Ronquillo R Varma A Deeks SG McCune JM Nixon DF Sinclair E Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells J Immunol Methods 2003, 283:141-53 10.1016/j.jim.2003.09.001 14659906
11. Rehermann B Naoumov NV Immunological techniques in viral hepatitis J Hepatol 2007, 46:508-20 10.1016/j.jhep.2007.01.002 17239482
12. Goonetilleke N Moore S Dally L Winstone N Cebere I Mahmoud A Pinheiro S Gillespie G Brown D Loach V Roberts J Guimaraes-Walker A Hayes P Loughran K Smith C De Bont J Verlinde C Vooijs D Schmidt C Boaz M Gilmour J Fast P Dorrell L Hanke T McMichael AJ Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes J Virol 2006, 80:4717-28 1472051 16641265 10.1128/JVI.80.10.4717-4728.2006
13. Boulet S Ndongala ML Peretz Y Boisvert MP Boulassel MR Tremblay C Routy JP Sekaly RP Bernard NF A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses J Immunol Methods 2007, 320:18-29 10.1016/j.jim.2006.11.010 17222422
14. Perfetto SP Chattopadhyay PK Roederer M Seventeen-colour flow cytometry: unravelling the immune system Nat Rev Immunol 2004, 4:648-55 10.1038/ nri1416 15286731
15. Horton H Thomas EP Stucky JA Frank I Moodie Z Huang Y Chiu YL McElrath MJ De Rosa SC Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination J Immunol Methods 2007, 323:39-54 10.1016/ j.jim.2007.03.002 17451739
16. Nomura LE Emu B Hoh R Haaland P Deeks SG Martin JN McCune JM Nixon DF Maecker HT IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells AIDS Res Ther 2006, 3:18 1562434 16859558 10.1186/1742-6405-3-18
17. Kern F LiPira G Gratama JW Manca F Roederer M Measuring Ag-specific immune responses: Understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer Trends Immunol 2005, 26:477-84 10.1016/j.it.2005.07.005 16039158
18. Sun Y Iglesias E Samri A Kamkamidze G Decoville T Carcelain G Autran B A systematic comparison of methods to measure HIV-1 specific CD8 T cells J Immunol Methods 2003, 272:23-34 10.1016/S0022-1759(02)00328-9 12505709
19. Deeks SG Walker BD Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy Immunity 2007, 27:406-16 10.1016/j.immuni.2007.08.010 17892849
20. Addo MM Yu XG Rathod A Cohen D Eldridge RL Strick D Johnston MN Corcoran C Wurcel AG Fitzpatrick CA Feeney ME Rodriguez WR Basgoz N Draenert R Stone DR Brander C Goulder PJ Rosenberg ES Altfeld M Walker BD Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load J Virol 2003, 77:2081-92 140965 12525643 10.1128/ JVI.77.3.2081-2092.2003
21. Masemola A Mashishi T Khoury G Mohube P Mokgotho P Vardas E Colvin M Zijenah L Katzenstein D Musonda R Allen S Kumwenda N Taha T Gray G McIntyre J Karim SA Sheppard HW Gray CM Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load J Virol 2004, 78:3233-43 371059 15016844 10.1128/JVI.78.7.3233-3243.2004
22. Gea-Banacloche JC Migueles SA Martino L Shupert WL McNeil AC Sabbaghian MS Ehler L Prussin C Stevens R Lambert L Altman J Hallahan CW de Quiros JC Connors M Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors J Immunol 2000, 165:1082-92 10878387
23. Betts MR Nason MC West SM De Rosa SC Migueles SA Abraham J Lederman MM Benito JM Goepfert PA Connors M Roederer M Koup RA HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells Blood 2006, 107:4781-9 1895811 16467198 10.1182/blood-2005-12-4818
24. Addo MM Draenert R Rathod A Verrill CL Davis BT Gandhi RT Robbins GK Basgoz NO Stone DR Cohen DE Johnston MN Flynn T Wurcel AG Rosenberg ES Altfeld M Walker BD Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection PLoS ONE 2007, 2:e321 1824710 17389912 10.1371/ journal.pone.0000321
25. Northfield JW Loo CP Barbour JD Spotts G Hecht FM Klenerman P Nixon DF Michaelsson J Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point J Virol 2007, 81:5759-65 1900265 17376902 10.1128/JVI.00045-07
26. Sallusto F Lenig D Forster R Lipp M Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 1999, 401:708-12 10.1038/44385 10537110
27. Janetzki S Panageas KS Ben-Porat L Boyer J Britten CM Clay TM Kalos M Maecker HT Romero P Yuan J Kast WM Hoos A Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother 2008, 57:303-15 2150634 17721781 10.1007/s00262-007-0380-6
28. Makedonas G Betts MR Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection Springer Semin Immunopathol 2006, 28:209-19 10.1007/s00281-006-0025-4 16932955
29. Seder RA Darrah PA Roederer M T-cell quality in memory and protection: implications for vaccine design Nat Rev Immunol 2008, 8:247-58 10.1038/ nri2274 18323851
30. Sekaly RP The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J Exp Med 2008, 205:7-12 2234358 18195078 10.1084/jem.20072681
31. Korber B BC Haynes B Moore J Koup R Kuiken C Walker B Watkins D HIV Molecular Immunology Los Alamos, NM: Los Alamos National Laboratories 2001
32. Cosma A Nagaraj R Buhler S Hinkula J Busch DH Sutter G Goebel FD Erfle V Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals Vaccine 2003, 22:21-9 10.1016/S0264-410X(03)00538-3 14604567
33. Vardas E Butto S Glashoff R Malnati MS Poli G Clerici M Preparing for phase II/III HIV vaccine trials in Africa Microbes Infect 2005, 7:1436-44 16257561
34. Pohla H Frankenberger B Stadlbauer B Oberneder R Hofstetter A Willimsky G Pezzutto A Dorken B Blankenstein T Schendel DJ Allogeneic vaccination for renal cell carcinoma: Development and monitoring Bone Marrow Transplant 2000, 25(Suppl 2):S83-7 10.1038/sj.bmt.1702362 10933197